Fangsheng Pharmaceutical announced that the company's innovative traditional Chinese medicine research and development project Shuangzao Anshen Granules received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration on October 30, 2026, and agreed to carry out clinical trials of this product for chronic insomnia. The drug is registered and classified as class 1.1 of traditional Chinese medicine. As of the date of disclosure of the announcement, the total R&D investment was about 4.612,000 yuan, and it has not yet been marketed at home or abroad.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.